ME1209, CP-6679

Beta-lactam (cephalosporin)
Meiji Seika Kaisha, Japan
1995
  • Highest development stage: Preclinical

  • Development dropped

  • Gram-positive activity

  • Gram-negative activity

  • Propensity to select resistant bacteria Lower propensity to select for resistant strains than ceftazidime

  • Mechanism of Action/Target pathogen: Similar activity to ceftazidime, cefeprime, and cefozopran against a clinical isolate of MRSA but against ceftazidime resistant mutant or aztreonam- resistant MRSA, ME1209 had lower MICs by at least 4 fold.

  • Additional information: Yoshida T, Ida I, Kurazono M, et al. ME1209 (CP6679), a new parenteral Cephalosporin II. In vitro and in vivo activity against Pseudomonas aeruginosa. 38th Intersci Conf Antimicrob Agents Chemother. 1998.

  • Compound/Drug Structure: https://pubchem.ncbi.nlm.nih.gov/substance/273351054